

ORGANIZING COMMITTEE

Paula Marques Alves

Animal Cell Technology Unit
IBET/ITQB-UNL

Apartado 12, 2780-901 Oeiras, Portugal
E-mail: marques@ibet.pt

Joaquim Vives

Servei de Teràpia Cel·lular
Banc de Sang i Teixits

Edifici Doctor Frederic Duran i Jordà
Passeig Taulat, 116, 08005 Barcelona
E-mail: jvives@bst.cat

Eric J Kremer

IGMM CNRS, Institut de Génétique Moléculaire de Montpellier
1919 rt de Mende, Montpellier, 34293, France
E-mail: eric.kremer@igmm.cnrs.fr

FEE and APPLICATION

EUR 150 for academic participants and

EUR 250 for industry participants.

The fee covers course registration and e-course book.

A **limited number of grants**, covering the course fee (not travel cost), are provided by ESACT and ACTIP. Applicants to the grants should indicate it in the course application, together with a motivation statement. Priority will be given to young PhD students from Academia.

All applications should be sent before 1st of September. Accepted applicants will be notified by September 12th and should register and complete payment by September 30th, 2021 at the latest.

CONTACT

Updated information will be available at ESACT website
(www.esact.org)

mailto:office@esact.org

AIM

With the 1st Bioprocessing and Manufacturing of Gene and Cell Therapy Products Course, ESACT is introducing this activity as one more contribution to the community targeting the use of viral vectors, stem cells and immune cells for therapy.

COURSE OUTLINE

This inaugural course is intended for Ph.D. students, post-docs, junior scientists, engineers, and clinicians searching to improve their understanding of the development and manufacturing of gene and cell therapy products. The speakers will address key bioprocessing aspects, analytical toolsets to assess the quantity and quality attributes, and regulatory challenges for the manufacturing of ATMPs, providing also a solid fundamental basis on vectorology and stem cell biology.

The course comprises lectures covering the main topics of Gene & Cell Therapy:

- Introduction to Gene Therapy & to Cell Therapy
- Immunology, Virology & Vectorology
- Cell Line Development for Viruses Production
- Stem Cell Biology
- Gene Modification of Cells for Therapy
- Bioreactor scale-up, scale down and single use Bioreactor for Cells based Products & Viral Vectors
- Downstream processing for Cells based Products & Viral Vectors
- Omics in Bioprocess Development
- Manufacturing Cells based Products & Viral Vectors
- Novel Modalities in Gene & Cell Therapy
- Scale-up and the Role of Automation in Gene & Cell Therapy
- Process & Product Analytics
- Health Technology Assessment/Economics
- Decision Tools

The program has also slots dedicated to presentation of case studies by lecturers, workshops, exercises, and discussion groups with the lecturers.

LECTURERS

Confirmed Lecturers: Eric Kremer (CNRS, France), Joaquim Vives (BST, Spain), Paula Alves (iBET, Portugal), Ana Coroadinha (ITQB NOVA, Portugal), Chantal Martin (Turnstone, Canada), Eoin McGrath (EBMT, Spain), Francesca Rosseti, (AGC Biologics, Italy), Ioannis Papantouniou (KU Leuven; Belgium); Kerry Fisher (Univ. Oxford, UK); Margarida Serra (FCT NOVA, Portugal); Mercedes Segura (AvroBio, USA)



BIOPROCESSING & MANUFACTURING GENE AND CELL THERAPY PRODUCTS

FIRST EDITION

October 4th - 8th, 2021

Virtual Course



Photos: www.ibet.pt

With the contribution of:



ACTIP

PROGRAM

	Monday Oct 4.2021	Tuesday Oct 5.2021	Wednesday Oct 6.2021	Thursday Oct 7.2021	Friday Oct 8.2021
13.00 - 13.50	Introduction to the Course Participants Presentations (EK/JV/PA)	Cell Line Development for Viruses Production (ASC)	Cell-based Therapeutics for Personalised Medicine (JV)	Scale-up and the Role of Automation in G & C T (FR)	The Road for Making Gene and Cell Therapy Products (KF)
Break – 10 min					
14.00 - 14.50	Introduction to Gene Therapy (ASC)	Upstream: Introduction to Production Technologies and Bioreactors (GuidaS)	Stem Cell Biology and Therapeutic Opportunities (JV)	Analytical and Potency Assays QC/QA (FR)	Regulatory Aspects Relevant for Cell and Gene Therapies (EM)
Break – 10 min					
15.00 - 15.50	Turning a Virus into Gene Transfer Vector (EK)	Principles of Downstream (IP)	Manufacturing: UP & DSP Processing of Cells (IP)	Successful Tech Transfer of Autologous Manufacturing (CM)	Health Technology Assessment/Economics (EM)
Break – 10 min					
16.00 - 16.50	Vector Immunogenicity - the Why and How (EK)	Omics in Bioprocess Development (GuidaS)	Cell-based Therapy Control Strategy Based on TR81 (MS)	Lentiviral Vector Manufacturing Platforms for Cell and Gene Therapies – Case Study Exercise (MS)	Wrap Up Session and Course Closing (PA/EK/JV)

Course will be held live; all times are Central European Summer Time (CEST).

APPLICATION

Deadline for online application is September 1, 2021. The number of participants is limited. Selection will be made based on CV of applicants and motivation letter

Online registration at
www.esact.org/courses

Updated information available on www.esact.org

Thanks to our sponsor of grants: **ACTIP**

CONTACT

more details, information, and registration at
www.esact.org

ESACT Office
email: office@esact.org